Intel stock spikes after report of possible US government stake
Investing.com - Citizens JMP has reiterated its Market Outperform rating and $33.00 price target on Abivax (NASDAQ:ABVX) ahead of upcoming clinical trial results. The target represents a significant premium to the current stock price of $8.27, though analysts’ targets range from $12 to $50, according to InvestingPro data.
The firm maintains its positive outlook on Abivax as the company prepares to report top-line results from its Phase 3 ABTECT trials evaluating obefazimod in moderate-to-severe ulcerative colitis in the third quarter of 2025. The stock has shown strong momentum, gaining over 34% in the past six months despite broader market volatility.
Citizens JMP expressed confidence in the potential for positive results based on the strong efficacy and safety profile demonstrated in earlier Phase 2b trials, as well as the optimized design of the Phase 3 study.
The $33 price target is derived from a risk-adjusted, discounted cash flow (DCF) analysis, according to the research firm.
Citizens JMP identified the upcoming Abivax clinical data as one of two high-conviction clinical catalysts in its coverage universe for the third quarter of 2025.
In other recent news, Abivax has made significant strides in the development of its lead drug candidate, obefazimod, for the treatment of ulcerative colitis. The company announced the completion of enrollment for its Phase 3 induction trials, with results expected in the third quarter of 2025. JMP Securities maintained its Market Outperform rating on Abivax, with a price target of $33.00, citing the strong efficacy and safety profile from earlier trials and the potential positive outcomes of the Phase 3 trials. Piper Sandler also reiterated an Overweight rating and a $42.00 price target, expressing confidence in obefazimod’s differentiated profile and potential combination use. Additionally, Abivax appointed Dr. Dominik Höchli, an immunology expert, to its Board of Directors, a move expected to enhance strategic insights as the company approaches key trial results. Dr. Höchli’s experience in global medical affairs and immunology is anticipated to be instrumental during this critical phase. Investors are encouraged to monitor these developments, keeping in mind the inherent risks and uncertainties of drug development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.